SYDNEY: Bega Cheese (ASX: BGA) announced the appointment of Pete Findlay as Chief Operating Officer having responsibility for the branded business segment. Pete joined Bega in November 2019 as Chief Financial Officer and is a member of the senior executive team. Pete has over 20 years’ experience in professional services and senior finance and operational…
Month: June 2022
Inify Laboratories appoints Dr. Claes Lind as Chief Medical Officer
STOCKHOLM: Inify Laboratories announces the addition of specialized medical competence to the company’s management team and organization. “We warmly welcome Dr. Claes Lind to the role as Chief Medical Officer (CMO). His impressive background in clinical diagnostics and education fits us perfectly. He will play an instrumental role in our establishment and expansion phase. The…
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
PARIS: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Ipsen is seeking approval of palovarotene, an oral, selective retinoic-acid receptor…
Bureau Veritas acquires Advanced Testing Laboratory, a US leader in scientific sourcing
PARIS: Bureau Veritas, a world leader in testing, inspection and certification, announced the acquisition of Advanced Testing Laboratory (ATL), a leader in scientific sourcing services for the North American Consumer Healthcare Products, Cosmetics & Personal Care and Medical Device markets. Headquartered in Cincinnati, Ohio, ATL’s services span the entire product life cycle, from research…
Voyager launches CBD Refillery
LONDON, UK: Voyager, the health and wellness company supplying high-quality Cannabidiol (CBD), hemp seed oil and hemp-related products, has launched a range of refillable CBD products with a new “CBD Refillery” now available at each of its stores in Dundee, St Andrews and Edinburgh. Made by Voyager in Perth (Scotland), the refillable range comprises eight…
Novacyt launches monkeypox assay in response to the outbreak
PARIS: Novacyt, an international specialist in clinical diagnostics, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) monkeypox assay in response to the recent outbreak of the virus in non-endemic countries. The launch of this assay expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to…
U.S. Government to support expansion of Croda lipid systems capability
LONDON: Croda International Plc, the company that uses smart science to create high performance ingredients and technologies that improve lives, announces that it has entered into a cooperative agreement with the United States (‘U.S.’) government in which the government will provide up to $75 million to expand the company’s U.S. manufacturing capacity of ingredients for…
poLight ASA signs a Proof-of-Concept agreement with a top tier medical customer
HORTEN: poLight ASA (OSE: PLT) announced that the company has signed an agreement to support a phased PoC (Proof of Concept) endoscopic camera system development with an unnamed top tier medical device customer. The total fee value of this POC agreement is approximately NOK 1.700.000 and is expected to be received across four phases between…
Genflow signs research agreement with Magnitude Biosciences Limited
LONDON: Genflow (LSE: GENF) has entered into a research agreement with Magnitude Biosciences Limited (“Magnitude”), a UK-based, specialist biotechnology research organisation that supports drug discovery and product development. Founded in 2018 as a Durham University spin out, Magnitude provides an automated service to identify health-span extending drugs faster and more cost effectively than current approaches….
Lynparza recommended in EU for early breast cancer
LONDON: AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) who have HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. The Committee for Medicinal Products for…